The effect of timing in the administration of hepatocyte growth factor to modulate BMP-2-induced osteoblast differentiation

Toshiki Kawasaki, Yasuo Niki, Takeshi Miyamoto, Keisuke Horiuchi, Morio Matsumoto, Mamoru Aizawa, Yoshiaki Toyama

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Development of bone morphogenetic protein (BMP) signaling modulators may provide useful therapeutic options for the treatment of large bony defects in clinical settings. Controversy remains over whether hepatocyte growth factor (HGF) is a positive or negative modulator of BMP-induced osteogenesis. This study analyzed osteogenic properties of HGF, particularly during BMP-2-induced bone formation. Using a mouse model of ectopic bone formation, HGF-impregnated gelatin sponges displayed significantly reduced bone formation induced by BMP-2, both radiologically and histologically. Abrogation of endogenous HGF production by knockdown of HGF mRNA resulted in upregulation of BMP-2-induced ALP activity for C2C12 myoblasts in vitro. In contrast, addition of exogenous HGF inhibited BMP-2-induced ALP activity and osteocalcin production by mouse embryonic fibroblasts (MEFs) through HGF-c-Met interactions. Inhibition of ALP activity by HGF was rescued by U0126, a MEK1/2 inhibitor, indicating that HGF suppresses the BMP-2-Smad axis via activation of ERK1/2. Importantly, treatment with HGF prior to administration of BMP-2 induced cellular proliferation of MEFs and did not influence subsequent osteoblast differentiation induced by BMP-2. The effects of HGF may differ according to the differentiation stage of mesenchymal stem cells, which would explain the inconsistencies seen in osteogenic properties of HGF in previous reports. The timing of HGF treatment is critical and should be carefully determined for successful induction of bone formation by BMPs.

Original languageEnglish
Pages (from-to)1191-1198
Number of pages8
JournalBiomaterials
Volume31
Issue number6
DOIs
Publication statusPublished - 2010 Feb

Fingerprint

Bone Morphogenetic Protein 2
Hepatocyte Growth Factor
Osteoblasts
Bone
Proteins
Osteogenesis
Bone Morphogenetic Proteins
Fibroblasts
Intercellular Signaling Peptides and Proteins
Hepatocytes
Modulators
Myoblasts
Osteocalcin
Porifera
Gelatin
Stem cells
Mesenchymal Stromal Cells

Keywords

  • BMP (bone morphogenetic protein)
  • Bone formation
  • HGF (hepatocyte growth factor)
  • Osteoblast differentiation
  • Tissue engineering

ASJC Scopus subject areas

  • Biomaterials
  • Bioengineering
  • Ceramics and Composites
  • Mechanics of Materials
  • Biophysics

Cite this

The effect of timing in the administration of hepatocyte growth factor to modulate BMP-2-induced osteoblast differentiation. / Kawasaki, Toshiki; Niki, Yasuo; Miyamoto, Takeshi; Horiuchi, Keisuke; Matsumoto, Morio; Aizawa, Mamoru; Toyama, Yoshiaki.

In: Biomaterials, Vol. 31, No. 6, 02.2010, p. 1191-1198.

Research output: Contribution to journalArticle

Kawasaki, Toshiki ; Niki, Yasuo ; Miyamoto, Takeshi ; Horiuchi, Keisuke ; Matsumoto, Morio ; Aizawa, Mamoru ; Toyama, Yoshiaki. / The effect of timing in the administration of hepatocyte growth factor to modulate BMP-2-induced osteoblast differentiation. In: Biomaterials. 2010 ; Vol. 31, No. 6. pp. 1191-1198.
@article{8f223e1e26314a379cfd7357b8b3eeef,
title = "The effect of timing in the administration of hepatocyte growth factor to modulate BMP-2-induced osteoblast differentiation",
abstract = "Development of bone morphogenetic protein (BMP) signaling modulators may provide useful therapeutic options for the treatment of large bony defects in clinical settings. Controversy remains over whether hepatocyte growth factor (HGF) is a positive or negative modulator of BMP-induced osteogenesis. This study analyzed osteogenic properties of HGF, particularly during BMP-2-induced bone formation. Using a mouse model of ectopic bone formation, HGF-impregnated gelatin sponges displayed significantly reduced bone formation induced by BMP-2, both radiologically and histologically. Abrogation of endogenous HGF production by knockdown of HGF mRNA resulted in upregulation of BMP-2-induced ALP activity for C2C12 myoblasts in vitro. In contrast, addition of exogenous HGF inhibited BMP-2-induced ALP activity and osteocalcin production by mouse embryonic fibroblasts (MEFs) through HGF-c-Met interactions. Inhibition of ALP activity by HGF was rescued by U0126, a MEK1/2 inhibitor, indicating that HGF suppresses the BMP-2-Smad axis via activation of ERK1/2. Importantly, treatment with HGF prior to administration of BMP-2 induced cellular proliferation of MEFs and did not influence subsequent osteoblast differentiation induced by BMP-2. The effects of HGF may differ according to the differentiation stage of mesenchymal stem cells, which would explain the inconsistencies seen in osteogenic properties of HGF in previous reports. The timing of HGF treatment is critical and should be carefully determined for successful induction of bone formation by BMPs.",
keywords = "BMP (bone morphogenetic protein), Bone formation, HGF (hepatocyte growth factor), Osteoblast differentiation, Tissue engineering",
author = "Toshiki Kawasaki and Yasuo Niki and Takeshi Miyamoto and Keisuke Horiuchi and Morio Matsumoto and Mamoru Aizawa and Yoshiaki Toyama",
year = "2010",
month = "2",
doi = "10.1016/j.biomaterials.2009.10.048",
language = "English",
volume = "31",
pages = "1191--1198",
journal = "Biomaterials",
issn = "0142-9612",
publisher = "Elsevier BV",
number = "6",

}

TY - JOUR

T1 - The effect of timing in the administration of hepatocyte growth factor to modulate BMP-2-induced osteoblast differentiation

AU - Kawasaki, Toshiki

AU - Niki, Yasuo

AU - Miyamoto, Takeshi

AU - Horiuchi, Keisuke

AU - Matsumoto, Morio

AU - Aizawa, Mamoru

AU - Toyama, Yoshiaki

PY - 2010/2

Y1 - 2010/2

N2 - Development of bone morphogenetic protein (BMP) signaling modulators may provide useful therapeutic options for the treatment of large bony defects in clinical settings. Controversy remains over whether hepatocyte growth factor (HGF) is a positive or negative modulator of BMP-induced osteogenesis. This study analyzed osteogenic properties of HGF, particularly during BMP-2-induced bone formation. Using a mouse model of ectopic bone formation, HGF-impregnated gelatin sponges displayed significantly reduced bone formation induced by BMP-2, both radiologically and histologically. Abrogation of endogenous HGF production by knockdown of HGF mRNA resulted in upregulation of BMP-2-induced ALP activity for C2C12 myoblasts in vitro. In contrast, addition of exogenous HGF inhibited BMP-2-induced ALP activity and osteocalcin production by mouse embryonic fibroblasts (MEFs) through HGF-c-Met interactions. Inhibition of ALP activity by HGF was rescued by U0126, a MEK1/2 inhibitor, indicating that HGF suppresses the BMP-2-Smad axis via activation of ERK1/2. Importantly, treatment with HGF prior to administration of BMP-2 induced cellular proliferation of MEFs and did not influence subsequent osteoblast differentiation induced by BMP-2. The effects of HGF may differ according to the differentiation stage of mesenchymal stem cells, which would explain the inconsistencies seen in osteogenic properties of HGF in previous reports. The timing of HGF treatment is critical and should be carefully determined for successful induction of bone formation by BMPs.

AB - Development of bone morphogenetic protein (BMP) signaling modulators may provide useful therapeutic options for the treatment of large bony defects in clinical settings. Controversy remains over whether hepatocyte growth factor (HGF) is a positive or negative modulator of BMP-induced osteogenesis. This study analyzed osteogenic properties of HGF, particularly during BMP-2-induced bone formation. Using a mouse model of ectopic bone formation, HGF-impregnated gelatin sponges displayed significantly reduced bone formation induced by BMP-2, both radiologically and histologically. Abrogation of endogenous HGF production by knockdown of HGF mRNA resulted in upregulation of BMP-2-induced ALP activity for C2C12 myoblasts in vitro. In contrast, addition of exogenous HGF inhibited BMP-2-induced ALP activity and osteocalcin production by mouse embryonic fibroblasts (MEFs) through HGF-c-Met interactions. Inhibition of ALP activity by HGF was rescued by U0126, a MEK1/2 inhibitor, indicating that HGF suppresses the BMP-2-Smad axis via activation of ERK1/2. Importantly, treatment with HGF prior to administration of BMP-2 induced cellular proliferation of MEFs and did not influence subsequent osteoblast differentiation induced by BMP-2. The effects of HGF may differ according to the differentiation stage of mesenchymal stem cells, which would explain the inconsistencies seen in osteogenic properties of HGF in previous reports. The timing of HGF treatment is critical and should be carefully determined for successful induction of bone formation by BMPs.

KW - BMP (bone morphogenetic protein)

KW - Bone formation

KW - HGF (hepatocyte growth factor)

KW - Osteoblast differentiation

KW - Tissue engineering

UR - http://www.scopus.com/inward/record.url?scp=72149116701&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72149116701&partnerID=8YFLogxK

U2 - 10.1016/j.biomaterials.2009.10.048

DO - 10.1016/j.biomaterials.2009.10.048

M3 - Article

VL - 31

SP - 1191

EP - 1198

JO - Biomaterials

JF - Biomaterials

SN - 0142-9612

IS - 6

ER -